Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification.

Cell Line, Tumor Bibenzyls / pharmacology Phenol Antineoplastic Agents / pharmacology
Anticancer effect Erianin Molecular mechanisms Structure modification Structure-activity relationships

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 06 08 2023
revised: 17 09 2023
accepted: 27 09 2023
medline: 3 11 2023
pubmed: 8 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

Erianin, a bioactive compound extracted from Dendrobium, a traditional Chinese medicine, exhibits remarkable anti-cancer properties through diverse molecular mechanisms and has attracted the attention of medicinal chemists. However, the low solubility in water, rapid metabolism and elimination from the body lead to poor bioavailability of Erianin, and greatly hinder its clinical application. The development of new Erianin derivatives is continuously proceed to improve its anticancer effects. In recent years, although important progress in the development of Erianin and the publication of some reviews in this aspect, the mechanism against various cancers, pharmacokinetic study, structural modification as well as structure-activity relationships have not been thoroughly considered. This review is aimed at providing complete picture regarding the above aspects by reviewing studies from 2000 to 2023.06. This review also supplies some important viewpoints on the design and future directions for the development of Erianin derivatives as possible clinically effective anticancer agents.

Identifiants

DOI: 10.1016/j.ejmech.2023.115844 PMID: 37804769
pubmed: 37804769
pii: S0223-5234(23)00811-5
doi: 10.1016/j.ejmech.2023.115844
pii:
doi:

Substances chimiques

Erianin 0
Bibenzyls 0
Phenol 339NCG44TV
Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115844

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflicts of interest.

Auteurs

Lu Ma (L)

Basic Medical Research Center, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, 450001, China.

Menglong Li (M)

Basic Medical Research Center, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, 450001, China.

Yueteng Zhang (Y)

Basic Medical Research Center, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, 450001, China. Electronic address: yuetengzhang@zzu.edu.cn.

Kangdong Liu (K)

Basic Medical Research Center, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, 450001, China; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China. Electronic address: kdliu@zzu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee et al.
1.00
T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Patients' knowledge about renal secondary effects of anti-tumoral drugs and renal protection measures.

Pauline Corbaux, Matthieu Bainaud, Adrien Rousseau et al.
1.00
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Recent advances of antitumor leading compound...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzyliques › Bibenzyles › Recent advances of antitumor leading compound...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Phénol › Recent advances of antitumor leading compound...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Recent advances of antitumor leading compound...